Sk Biopharmaceutica Ownership

326030 Stock   103,800  500.00  0.48%   
Sk Biopharmaceuticals secures a total of 78.31 Million outstanding shares. Sk Biopharmaceuticals owns majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.28 % of Sk Biopharmaceuticals Co outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company retains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Sk Biopharmaceutica in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Sk Biopharmaceutica, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Sk Biopharmaceuticals Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

326030 Stock Ownership Analysis

About 64.0% of the company shares are owned by insiders or employees . The company recorded a loss per share of 117.74. Sk Biopharmaceuticals had not issued any dividends in recent years. For more info on Sk Biopharmaceuticals Co please contact Dong Lee at 82 31 8093 0114 or go to https://www.skbp.com.

Sk Biopharmaceutica Outstanding Bonds

Sk Biopharmaceutica issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sk Biopharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most 326030 bonds can be classified according to their maturity, which is the date when Sk Biopharmaceuticals Co has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Pair Trading with Sk Biopharmaceutica

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sk Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sk Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.

Moving together with 326030 Stock

  0.77207940 Samsung BiologicsPairCorr
  0.91298380 ABL BioPairCorr
  0.86144510 Green Cross LabPairCorr

Moving against 326030 Stock

  0.63035420 NaverPairCorr
  0.63011200 HMM CoPairCorr
  0.61032640 LG UplusPairCorr
  0.41003535 Hanwha InvestmentSecuriPairCorr
  0.4039240 Gyeongnam SteelPairCorr
The ability to find closely correlated positions to Sk Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sk Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sk Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sk Biopharmaceuticals Co to buy it.
The correlation of Sk Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sk Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sk Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sk Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in 326030 Stock

Sk Biopharmaceutica financial ratios help investors to determine whether 326030 Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 326030 with respect to the benefits of owning Sk Biopharmaceutica security.